Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MESO
stocks logo

MESO

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
1 Analyst Rating
up Image0
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image0
Current: 12.440
sliders
Low
30.00
Averages
30.00
High
30.00
up Image0
Current: 12.440
sliders
Low
30.00
Averages
30.00
High
30.00
Piper Sandler
Edward Tenthoff
Buy
Reiterates
$15 → $24
2025-02-07
Reason
Piper Sandler
Edward Tenthoff
Price Target
$15 → $24
2025-02-07
Reiterates
Buy
Reason
Jefferies
David Stanton
Strong Buy
to
Hold
Downgrades
n/a
2024-12-23
Reason
Jefferies
David Stanton
Price Target
n/a
2024-12-23
Downgrades
Strong Buy
to
Hold
Reason
Jefferies downgraded Mesoblast to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company's for the FDA'ss recent approval of Ryoncil in pediatric steroids-refractory acute graft-versus-host disease patients. While the market size is only 375 pediatric patients per year in the U.S., expansion of this indication is possible in adults if the upcoming adult trial is positive, the analyst tells investors in a research note. Jefferies continues to assume full U.S. reimbursement approval at the start of fiscal 2026. However, after Mesoblast's recent share price appreciation, the firm downgraded the shares on valuation.
Piper Sandler
Edward Tenthoff
Buy
Maintains
$11 → $15
2024-12-19
Reason
Piper Sandler
Edward Tenthoff
Price Target
$11 → $15
2024-12-19
Maintains
Buy
Reason
Maxim Group
Jason McCarthy
Hold
to
Strong Buy
Upgrades
$12
2024-09-24
Reason
Maxim Group
Jason McCarthy
Price Target
$12
2024-09-24
Upgrades
Hold
to
Strong Buy
Reason
Maxim upgraded Mesoblast to Buy from Hold with a $12 price target.
Cantor Fitzgerald
Louise Chen
Buy
Reiterates
n/a
2024-08-29
Reason
Cantor Fitzgerald
Louise Chen
Price Target
n/a
2024-08-29
Reiterates
Buy
Reason
Jefferies
David Stanton
Hold
to
Strong Buy
Upgrades
n/a
2024-08-29
Reason
Jefferies
David Stanton
Price Target
n/a
2024-08-29
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mesoblast Ltd (MESO.O) is -19.51, compared to its 5-year average forward P/E of -10.76. For a more detailed relative valuation and DCF analysis to assess Mesoblast Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.76
Current PE
-19.51
Overvalued PE
-2.28
Undervalued PE
-19.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.67
Current EV/EBITDA
-28.47
Overvalued EV/EBITDA
6.26
Undervalued EV/EBITDA
-47.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
30.77
Current PS
28.49
Overvalued PS
48.87
Undervalued PS
12.67

Financials

Annual
Quarterly

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MESO News & Events

Events Timeline

(ET)
2025-06-12
05:18:33
Mesoblast gives update on Revascor accelerated approval, Ryoncil label extension
select
2025-05-15 (ET)
2025-05-15
05:38:10
Mesoblast gets years of orphan-drug exclusive approval from FDA for Ryoncil
select
2025-04-16 (ET)
2025-04-16
21:36:29
Mesoblast extends payer coverage for Ryoncil to over 100M U.S. lives
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.5
07-16Benzinga
PinnedBig Bucks For Better Barks: Gallant Lands $18M To Bring Game-Changing Stem Cell Therapies To Pets

  • Funding and Focus: San Diego biotech startup Gallant raised $18 million in a Series B financing round to develop ready-to-use stem cell therapies for pets, specifically targeting diseases in dogs and cats, rather than humans.

  • Market Potential: The company aims for FDA conditional approval by early 2026 for its treatment of feline chronic gingivostomatitis, with plans to expand into other conditions like canine osteoporosis and atopic dermatitis, addressing significant gaps in current veterinary care.

Preview
2.0
07-02Benzinga
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

  • Market Overview: U.S. stock futures are up, with Dow futures increasing by about 0.2%, while several healthcare stocks, including Centene Corporation, Molina Healthcare, and BrightView Holdings, experienced significant declines in pre-market trading due to lowered earnings guidance or other negative news.

  • Stock Performance: Centene shares fell sharply by 27.7% after withdrawing its 2025 earnings guidance; other notable declines include Molina Healthcare down 9%, BrightView Holdings down 8.8%, and Oscar Health down 8.3%.

Preview
9.5
07-02Benzinga
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

  • Greenbrier Companies Earnings Surge: The Greenbrier Companies, Inc. reported quarterly earnings of $1.86 per share, significantly exceeding market expectations of 98 cents, leading to a 13.1% increase in their stock price during pre-market trading.

  • Pre-Market Stock Movements: Various stocks experienced notable fluctuations in pre-market trading, with CID HoldCo, Inc. and Namib Minerals seeing substantial gains of over 150%, while BioNexus Gene Lab Corp. and Centene Corporation faced significant declines of over 25%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mesoblast Ltd (MESO) stock price today?

The current price of MESO is 12.44 USD — it has increased 9.6 % in the last trading day.

arrow icon

What is Mesoblast Ltd (MESO)'s business?

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

arrow icon

What is the price predicton of MESO Stock?

Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mesoblast Ltd (MESO)'s revenue for the last quarter?

Mesoblast Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Mesoblast Ltd (MESO)'s earnings per share (EPS) for the last quarter?

Mesoblast Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Mesoblast Ltd (MESO)'s fundamentals?

The market is revising Downward the revenue expectations for Mesoblast Limited (MESO) for FY2025, with the revenue forecasts being adjusted by -0.66% over the past three months. During the same period, the stock price has changed by 16.04%.
arrow icon

How many employees does Mesoblast Ltd (MESO). have?

Mesoblast Ltd (MESO) has 73 emplpoyees as of July 17 2025.

arrow icon

What is Mesoblast Ltd (MESO) market cap?

Today MESO has the market capitalization of 1.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free